Woodline Partners’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$167M Sell
8,000,013
-2,072,212
-21% -$28.8M 0.63% 17
2025
Q4
$89.2M Buy
10,072,225
+4,042,297
+67% +$34.8M 0.35% 58
2025
Q3
$50.7M Buy
6,029,928
+22
+0% +$149 0.24% 109
2025
Q2
$30.9M Buy
6,029,906
+5,523,718
+1,091% +$13.7M 0.16% 184
2025
Q1
$693K Buy
506,188
+111,791
+28% +$275K ﹤0.01% 801
2024
Q4
$1.22M Buy
+394,397
New +$1.83M 0.01% 731
2024
Q3
Sell
-348,091
Closed -$2.99M 703
2024
Q2
$2.99M Buy
+348,091
New +$2.69M 0.03% 385
2023
Q4
Sell
-250,000
Closed -$2.81M 656
2023
Q3
$2.81M Sell
250,000
-13,645
-5% -$83.2K 0.03% 369
2023
Q2
$875K Sell
263,645
-97,549
-27% -$351K 0.01% 496
2023
Q1
$1.43M Sell
361,194
-4,042
-1% -$23.5K 0.02% 451
2022
Q4
$2.65M Sell
365,236
-134,859
-27% -$949K 0.04% 435
2022
Q3
$1.81M Hold
500,095
0.03% 480
2022
Q2
$2.27M Hold
500,095
0.03% 409
2022
Q1
$3.79M Buy
500,095
+77
+0% +$667 0.06% 279
2021
Q4
$5.47M Sell
500,018
-22
-0% -$265 0.08% 273
2021
Q3
$6.47M Sell
500,040
-3,357
-0.7% -$40.2K 0.11% 223
2021
Q2
$5.73M Hold
503,397
0.11% 206
2021
Q1
$5.6M Hold
503,397
0.12% 180
2020
Q4
$5.76M Buy
503,397
+3,397
+0.7% +$35.8K 0.15% 149
2020
Q3
$5.18M Buy
+500,000
New +$5.11M 0.17% 126

Other funds holding TNGX

Woodline Partners's TNGX Position: Q1 2026 in Review

Woodline Partners reduced its Tango Therapeutics (TNGX) stake by 21% in Q1 2026, selling an estimated $28.8M and leaving 8,000,013 shares worth $167M. The position accounts for 0.63% of the portfolio, ranked #17.

Woodline Partners first reported a position in TNGX in Q3 2020 and has held it in 20 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Woodline Partners held 8,000,013 shares of Tango Therapeutics worth $167M as of Q1 2026.
  • Woodline Partners sold 2,072,212 Tango Therapeutics shares in Q1 2026, an estimated $28.8M.
  • Tango Therapeutics made up 0.63% of Woodline Partners's portfolio in Q1 2026, its #17 holding.
  • Woodline Partners first reported a position in Tango Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.